.Pharmacolibrary.Drugs.ATC.L.L01EX01 .Pharmacolibrary.Drugs.ATC.L.L01EX01| name: | Sunitinib |
| ATC code: | L01EX01 | route: | oral |
| n-compartments | 2 |
Sunitinib is an orally available, multi-targeted receptor tyrosine kinase inhibitor used primarily in the treatment of renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. It is currently approved and widely used in oncology.
Pharmacokinetics as described in adults with advanced solid tumors, following oral administration; typical population (no specified restrictions on age or sex); steady-state parameters after repeated dosing.
Mizuno, T, et al., & Matsubara, K (2014). The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Therapeutic drug monitoring 36(3) 310–316. DOI:10.1097/FTD.0000000000000025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24825438
Zhang, Y, et al., & Qu, H (2018). Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma. Oncotarget 9(18) 14109–14123. DOI:10.18632/oncotarget.23881 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29581831
Houk, BE, et al., & Amantea, M (2009). A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clinical cancer research : an official journal of the American Association for Cancer Research 15(7) 2497–2506. DOI:10.1158/1078-0432.CCR-08-1893 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19258444